Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Zacks01-17

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan Healthcare Conference. Among these, Moderna MRNA and Regeneron ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2504946880?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-17 01:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2504946880","market":"us","top_or_hot":-1,"title":"Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates","media":"Zacks","content":"<div>\n<p>It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan Healthcare Conference. Among these, Moderna MRNA and Regeneron ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-stock-roundup-mrna-ntla-170000544.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-17 01:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biotech-stock-roundup-mrna-ntla-170000544.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan Healthcare Conference. Among these, Moderna MRNA and Regeneron ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-stock-roundup-mrna-ntla-170000544.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-mrna-ntla-170000544.html","article_id":"2504946880","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504946880","pubTimestamp":1737046800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan Healthcare Conference. Among these, Moderna MRNA and Regeneron Pharmaceutical REGN were in the limelight on financial updates. Meanwhile, Intellia Therapeutics NTLA was down after it announced a strategic update and workforce reduction.Moderna reported preliminary product sales between $3 billion and $3.1 billion for 2024. This includes more than $3 billion in COVID-19 vaccine sales and minimal sales from the RSV vaccine mResvia. This figure was mainly toward the lower end of the company’s previously issued guidance of $3.0-$3.5 billion. Cash, cash equivalents and investments at year-end 2024 were approximately $9.5 billion.However, Moderna cut its previously announced sales guidance for 2025 by $1 billion. It now forecasts total revenues to be in the range of $1.5-$2.5 billion, mainly from product sales of its COVID-19 and RSV vaccines. Management expects to ge","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","MRNA":"Moderna, Inc.","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","NTLA":"Intellia Therapeutics Inc","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BIIB":"渤健公司","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","BK4548":"巴美列捷福持仓","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU0882574055.USD":"富达全球健康医疗A ACC","REGN":"再生元制药公司","BK4532":"文艺复兴科技持仓","SAGE":"Sage Therapeutics","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4007":"制药","GSK":"葛兰素史克","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4535":"淡马锡持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4501":"段永平概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4568":"美国抗疫概念","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4588":"碎股","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","GSK.UK":"葛兰素史克"},"translate_title":"生物技术股票综述：MRNA、NTLA因更新而下跌，SAGE因Biogen的报价和其他更新而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1,"BIIB":1,"GSK":1,"MRNA":1,"NTLA":1,"REGN":1,"GSK.UK":0.6},"content_text":"It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan Healthcare Conference. Among these, Moderna MRNA and Regeneron Pharmaceutical REGN were in the limelight on financial updates. Meanwhile, Intellia Therapeutics NTLA was down after it announced a strategic update and workforce reduction.\nRecap of the Week’s Most Important Stories:\nMRNA Stock Down on Updates for 2025\nModerna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.\nModerna reported preliminary product sales between $3 billion and $3.1 billion for 2024. This includes more than $3 billion in COVID-19 vaccine sales and minimal sales from the RSV vaccine mResvia. This figure was mainly toward the lower end of the company’s previously issued guidance of $3.0-$3.5 billion. Cash, cash equivalents and investments at year-end 2024 were approximately $9.5 billion.\nHowever, Moderna cut its previously announced sales guidance for 2025 by $1 billion. It now forecasts total revenues to be in the range of $1.5-$2.5 billion, mainly from product sales of its COVID-19 and RSV vaccines. Management expects to generate the majority of this figure in the second half of the year. Shares of Moderna were down due to the guidance cut.\nModerna reiterated its stance to launch 10 new marketed products over the next three years. To achieve this goal, management submitted three regulatory filings seeking the FDA’s approval.\nNTLA Stock Down on Strategic Updates\nIntellia Therapeutics announced its strategic priorities and key anticipated milestones for 2025. However, investors were disappointed and the stock fell following the announcement.\nAs part of this portfolio reorganization, NTLA is planning to prioritize the development of its investigational in vivo genome-editing candidate, Nexiguran ziclumeran (nex-z, also known as NTLA-2001), which is being studied for two indications, ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy.\nIntellia is developing another pipeline candidate, NTLA-2002, for the treatment of hereditary angioedema. Intellia has decided to discontinue the development of its in vivo gene insertion candidate, NTLA-3001, for the treatment of alpha-1 antitrypsin deficiency associated lung disease.\nAlso, with the strategic reorganization, NTLA plans to reduce its current workforce by almost 27% over the course of 2025.\nNTLA had approximately $862 million in cash, cash equivalents and investments at the end of the fourth quarter of 2024. Per the company, the existing cash balance and the anticipated cost savings from the above-mentioned strategic reorganization are expected to provide the cash runway into the first half of 2027.\nNTLA currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nRegeneron's Pipeline Updates\nRegeneron provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference.\nOn a preliminary basis, lead drug Eylea and Eylea HD (higher dose of Eylea) recorded $6 billion in sales in 2024 in the United States. Sales for the fourth quarter amounted to $1.5 billion in the United States.  On a standalone basis, Eylea sales totaled $1.19 billion in the United States in the fourth quarter of 2024. Eylead HD’s net product sales were $305 million in the fourth quarter of 2024 in the United States.\nREGN filed an application with the FDA for the use of the Eylea HD pre-filled syringe. A potential approval and launch are expected by mid-2025. Longer-term data in wet age-related macular degeneration and diabetic macular edema are under FDA review, with a target action date of April 20, 2025. Regeneron plans to submit a supplemental biologics license application (sBLA) for Eylea HD for every four-week dosing and retinal vein occlusion in the first quarter of 2025 to maximize dosing flexibility and address more retinal diseases.\nAmong other updates, an application for expanding the Dupixent’s label for the indication of chronic spontaneous urticaria is under review in the United States with a target action date of April 18, 2025. The sBLA seeking label expansion of the drug for bullous pemphigoid was submitted in the fourth quarter of 2024.\nOncology drug Libtayo exceeded $1 billion in sales for 2024. Regeneron announced positive results from the late-stage C-POST study, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically significant and clinically meaningful improvement in the primary endpoint of disease-free survival in patients with high-risk cutaneous squamous cell carcinoma after surgery.\nRegeneron also announced a strategic collaboration with Truveta, Inc. and its collective of U.S. health systems to advance innovation and data-driven discovery across the life sciences, public health and healthcare delivery ecosystem.\nSAGE Stock Up on Biogen’s Offer\nSage Therapeutics SAGE announced that its partner Biogen made an unsolicited, non-binding proposal offer to acquire the former’s shares (that it does not already own) for $7.22 per share. The offer price represents a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan. 10.\nAccording to an SEC filing by the company, Biogen currently owns a 10.2% stake in SAGE. SAGE stock was up in response to the news. Sage Therapeutics’ board will review and evaluate the offer and make a final decision.\nSage Therapeutics and Biogen have a collaboration deal for the commercialization of Zurzuvae, which was approved for treating postpartum depression in August 2023.\nGSK to Acquire IDRx, Inc.\nGSK plc GSK announced an agreement to acquire clinical-stage private biotech IDRx, which makes precision therapeutics for treating gastrointestinal stromal tumors (GIST).  IDRx’s key pipeline candidate is IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI), which has shown the potential to address all key KIT mutations in GIST that drive tumor growth.\nPer the terms of the acquisition, GSK will make an upfront payment of $1 billion, along with potential milestone payments of $150 million in cash. The acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers, including ongoing trials with dostarlimab and GSK5764227.\nPerformance\nThe Nasdaq Biotechnology Index has lost 0.97% in the past four trading sessions and MRNA’s shares have lost 19.46%. In the past six months, shares of MRNA have plunge 71.38%. (See the last biotech stock roundup here: Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More)\n \nImage Source: Zacks Investment Research\nWhat's Next in Biotech?\nStay tuned for more pipeline updates. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRegeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report\nGSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report\nModerna, Inc. (MRNA) : Free Stock Analysis Report\nSage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report\nIntellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2504946880"}